ORIGINAL RESEARCH article
Front. Neurosci.
Sec. Neurodegeneration
Volume 19 - 2025 | doi: 10.3389/fnins.2025.1682274
This article is part of the Research TopicBiomarkers for the identification of effective treatments for neurodegenerative diseaseView all 4 articles
Revealing Cerebrospinal Fluid Biomarkers in Parkinson's Disease Dementia Based on iTRAQ Proteomics Research
Provisionally accepted
Lifen Chen1*
LIN HAN1
Ying Liu1Changhong Tan1Lijuan Mo1Huahua Su1Ping Ma2Guotao Zeng2Jianhe Yue2
Xi Liu1*- 1Department of Neurology, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
- 2Department of Neurosurgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: Parkinson's disease dementia (PDD) imposes a significant burden on patients and healthcare systems but currently lacks specific biomarkers. This study aimed to identify novel cerebrospinal fluid (CSF) biomarkers for PDD using proteomics and to explore their functional significance. Methods: Employing iTRAQ-based quantitative proteomics, we analyzed CSF from 73 participants included 34 PD patients, 14 PDD patients and and 25 healthy Controls (HCs). Bioinformatics analysis identified 44 differentially expressed proteins in PDD compared to PD (33 upregulated, 11 downregulated). Subsequent validation by ELISA confirmed a significant decrease in Insulin-like Growth Factor Binding Protein 3 (IGFBP3) concentration in PDD CSF compared to PD, while other candidates (NXPH1, LRRN1, HPRT1) showed no significant differences. In vitro functional studies using SH-SY5Y neuroblastoma cells demonstrated that IGFBP3 significantly attenuated cytotoxicity and apoptosis induced by the neurotoxin MPP⁺. IGFBP3 pretreatment improved cell viability (assessed by CCK-8 assay), reduced lactate dehydrogenase (LDH) release, and decreased apoptosis rates (measured by flow cytometry). Mechanistically, IGFBP3 counteracted MPP⁺-induced dysregulation of apoptosis markers (increased Bcl-2/Bax ratio; reduced cleaved caspase-3/caspase-3 ratio) and activated the PI3K/Akt/GSK3β signaling pathway by restoring phosphorylation levels of PI3K, Akt, and GSK3β. Results: These findings suggest that decreased CSF IGFBP3 is a potential biomarker for PDD. Furthermore, IGFBP3 exerts neuroprotective effects against MPP⁺ toxicity, likely mediated through the activation of PI3K/Akt/GSK3β pathway and inhibition of apoptosis. Conclusion: IGFBP3 warrants further investigation as a diagnostic biomarker and therapeutic target for PDD, necessitating future validation in larger cohorts and in vivo models.
Keywords: Proteomics, parkinson disease dementia(PDD), Cerebrospinal fluid(CSF), biomarker, isobaric tags for relative and absolute quantification(iTRAQ)
Received: 08 Aug 2025; Accepted: 17 Oct 2025.
Copyright: © 2025 Chen, HAN, Liu, Tan, Mo, Su, Ma, Zeng, Yue and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lifen Chen, lifen_chen@163.com
Xi Liu, tianwailiuxi@cqmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.